Products: Primary Antibodies

Anti-LRRK2/Dardarin (N3) (non-mouse-reactive) Antibody (N231B/34)

from NeuroMab

Product Summary:

Detect LRRK2/Dardarin (N3) with this antibody validated for IHC, WB, ICC.

PRODUCT OPTIONS

Brand	Catalog #	Option	Volume	Concentration	Price
Brand	Catalog # 75-266	Option Purified	Volume 100 µL	Concentration 1 mg/mL	Price $275.00
Brand	Catalog # 73-266	Option TC Supernatant	Volume 5 mL	Concentration Lot dependent	Price $275.00

"TC Supernatant" vs. "Purified"

TC Supernatant
Hybridoma tissue-culture supernatant (5mL) generally containing 10-50 ug/mL monoclonal antibody (clone-dependent) can be a very economical choice. Supernatant is suitable for most applications including Western Blot, immunocytochemistry, immunohistochemistry etc. For applications requiring higher antibody concentration or purity (such as immunoprecipitation, microinjection, or conjugation) it is recommended that you purchase the purified form of the antibody (supplied at 1mg/mL).

Purified mAbs
Produced by in vitro bioreactor culture of hybridoma lines followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody at 1mg/mL.

Validation Images

Product Details

Antibody Type:

Monoclonal

Host Species:

Mouse

Antibody Isotype:

IgG2a

Species Reactivity:

Human Mouse Rat

Applications:

ICC IHC WB

Target Description:

LRRK2 (also known as PARK8) encodes a protein with 5 putative functional domains: an N-terminal leucine-rich repeat (LRR) domain, a Roc (Ras of complex protein) domain that shares sequence homology to the Ras-related GTPase superfamily, a COR (C-terminal of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) domain, and a C-terminal WD40 repeat domain. Mutation in this gene is one of the most common causes of inherited Parkinson disease (Gandhi et al., 2008). LRRK2 was originally identified as a putative disease-causing transcript (DKFZp434H2111) within a 2.6-Mb region encompassing a locus for Parkinson disease-8 (PARK8). Northern blot analysis detected a 9-kb mRNA transcript in all tissues tested, including brain. The authors named the protein product dardarin, derived from the Basque word dardara, meaning tremor. LRRK2/dardarin is also known to positively regulate autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway and together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. LRRK2/PARK8 is also known to regulate neuronal process morphology in the intact central nervous system (CNS) and play a role in synaptic vesicle trafficking.

Immunogen:

Fusion protein amino acids 841-960 of human LRRK2 (also known as Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin and PARK8, accession numberQ5S007) Mouse: 81% identity (98/120 amino acids identical)
Rat: 80% identity (97/120 amino acids identical) 30% identity with LRRK1

Protein Name(s):

Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)

Gene Name(s):

LRRK2 PARK8

Antibody Registry ID:

Purified: AB_11000724
TC Supernatant: AB_11001669

Antibody Validation and Application Notes

This antibody has been validated using the following assays:

Knockout Validation:

This antibody has been knockout-validated in mouse brain (by Western blot and/or immunohistochemistry).

Western Blot:

This antibody recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.

Immunocytochemistry:

This antibody shows the expected staining pattern when used to stain COS cells overexpressing target.

Immunohistochemistry:

This antibody shows the expected immunoperoxidase-diaminobenzidine / immunofluorescence staining pattern when used to stain brain sections.

Molecular Weight:

>200 kDa

Quality Control

The following quality control assay is performed on each new lot of this antibody to ensure it meets designated performance requirements.

Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.

Citations and References

Choi I1,2,3, Kim B2, Byun JW1,2, Baik SH4, Huh YH5, Kim JH1,2, Mook-Jung I4, Song WK5, Shin JH6, Seo H7, Suh YH1,2,3, Jou I1,2,3, Park SM1,2,3, Kang HC8, Joe EH1,2,3,9,10.. (2015), 'LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase..' Nat Commun. . 10.1038/ncomms9255.
Davies P1, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL.. (2013), 'Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies..' Biochem J.. 10.1042/BJ20121742.
Belluzzi E1,2, Gonnelli A3, Cirnaru MD4, Marte A5, Plotegher N6,7, Russo I8, Civiero L9, Cogo S10, Carrion MP11, Franchin C12,13, Arrigoni G14,15, Beltramini M16, Bubacco L17, Onofri F18, Piccoli G19,20, Greggio E21.. (2016), 'LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate..' Mol Neurodegener.. 10.1186/s13024-015-0066-z.
Daher JP1, Volpicelli-Daley LA1, Blackburn JP1, Moehle MS1, West AB2.. (2014), 'Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats..' Proc Natl Acad Sci U S A.. 10.1073/pnas.1403215111.
Dorval V1, Mandemakers W2, Jolivette F1, Coudert L3, Mazroui R3, De Strooper B2, Hébert SS1.. (2014), 'Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models..' PLoS One.. 10.1371/journal.pone.0085510.